Lupin receives China Approval for Oseltamivir Phosphate Oral Suspension

Global pharma major Lupin Limited (Lupin) today announced that China's National Medical Products Administration has approved its Abbreviated New Drug Application for Oseltamivir Phosphate, in partnership with Yabao Pharmaceuticals, a leader in China's paediatric medicine market. This marks Lupin's first product entry into China - a significant milestone in its global expansion.

Oseltamivir Phosphate for oral suspension, 6 mg/mL will be launched and commercialized to expand access, particularly for paediatric use. This expands Lupin's global footprint and its commitment to delivering highquality, affordable medicines to patients and children in need.

Oseltamivir Phosphate for oral suspension, 6 mg (base)/mL is indicated:

- For treatment of influenza A and B in patients 2 weeks of age and older

- For prevention of influenza A and B in individuals 1 year of age and older

Fabrice Egros, President - Corporate Development, Lupin, said, "We are delighted that we have received approval for Oseltamivir Oral Suspension in China. This is a strategic step in our entry into one of the world's largest pharmaceutical markets. It reflects our shared commitment to expanding access to high-quality, affordable therapies, particularly in paediatric care. We look forward to building a stronger presence in this market through our partnership."

Wei Ren, President, Yabao, said, "We are pleased to announce the official approval of Oseltamivir Oral Suspension in China, marking a key milestone in our partnership with Lupin. It reinforces Yabao's dedication to quality paediatric medicines and showcases our strong collaboration. We will further expand our R&D portfolio for paediatric and adult chronic disease drugs to jointly advance our businesses."

Shares of Lupin Limited was last trading in BSE at Rs. 2279.50 as compared to the previous close of Rs. 2285.35. The total number of shares traded during the day was 83982 in over 3118 trades.

The stock hit an intraday high of Rs. 2304.90 and intraday low of 2270.00. The net turnover during the day was Rs. 191614181.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 Pharmaceuticals China Approval OseltamivirPhosphate OralSuspension